Macro: Sandcastle economics
Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.
Chief Investment Strategist
Summary: Our guess is that emerging market equities next year will do great as Asia is coming out of the Covid-19 pandemic much stronger than the developed world. China will most likely ease its financial conditions through monetary policy in the early part of 2021 lifting sentiment but also valuation multiples on emerging market equities. In 2021, earnings in emerging markets will come roaring back at an even more impressive rate than in the developed world creating a power positive tailwind of earnings surprises and strong earnings growth.
This week is starting with a clear divergence across equity markets with momentum stocks down (that is technology stocks) and the broader market bid indicating the value trade is being put on again. As we wrote on Friday, we would like to see the US 10-year yield move above 1-1.1% before we call the big rotation into value stocks. We are also observing emerging market equities being the best performing segment this morning on the backdrop of much better than expected South Korea exports y/y (first 20 days of November) out at 11.1% vs. est. -5.8% suggesting the cyclical part of the economy is really heating up. With China’s industrial growth back to levels seen before the Covid-19 pandemic there are many indicators suggesting strong growth in Asia which will reflect positively on emerging market equities which are driven by equities in South Korea, China, Taiwan and India.
Emerging market equities have outperformed developed equities by 10.5% since late June as sentiment has changed to the stance that the main emerging market indices (China, Taiwan, South Korea and India) will come out stronger as this part of the world has managed the pandemic much better than many developed market countries. The relative performance between emerging markets and developed markets also suggest that this a mean-reversion trade as emerging markets have underperformed for years as investors have focused on US technology and health care stocks.
One of the main reasons behind our positive view is that we guess China will ease its financial conditions through easier monetary policy. In many ways, China is running too tight financial conditions which have consistently strengthened the currency against the USD, but the length of these tighter conditions are now becoming an issue for export growth and the parts of the economy related to real estate. We expect China to ease monetary policy in 2021 which could lift equities through expanding valuation multiples.
Our other argument for being long emerging markets is that Chinese stimulus and a better positioned Asian economy will lift earnings considerably from current low levels. Analysts expect earnings to increase by 43% over the next 12 months which will likely create a lot of positive tailwind from earnings exceeding expectations and growing fast on a y/y basis which tend to lift sentiment. Analysts also discount 11-15% earnings growth in the years after 2021 which should also materialize in higher equity prices as investors will continue to look for growth.
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)